ArticleJournal of clinical microbiology2003
Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location.
Article in Journal of clinical microbiology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Twenty Years of the SENTRY Antifungal Surveillance Program: Results forOpen forum infectious diseases · 2019Article
- Review
- Multilocus Sequence Typing (MLST) Genotypes ofFrontiers in microbiology · 2018Article
- Comparative Genomics of Two SequentialG3 (Bethesda, Md.) · 2017Article
- Emerging Threats in Antifungal-Resistant Fungal Pathogens.Frontiers in medicine · 2016Review
- In Vitro Activity of Caspofungin Against Fluconazole-Resistant Candida Species Isolated From Clinical Samples in Iran.Jundishapur journal of microbiology · 2015Article
- Advances in the treatment of invasive neonatal candidiasis.Expert opinion on pharmacotherapy · 2015Review
- Patterns of human oral yeast species distribution on Hainan Island in China.Mycopathologia · 2013Article
- Triazole use in the nursery: fluconazole, voriconazole, posaconazole, and ravuconazole.Current drug metabolism · 2013Review
- Article
- Microarray and molecular analyses of the azole resistance mechanism in Candida glabrata oropharyngeal isolates.Antimicrobial agents and chemotherapy · 2010Article
- Risk factors for fluconazole-resistant candidemia.Antimicrobial agents and chemotherapy · 2010Article
- Skn7p is involved in oxidative stress response and virulence of Candida glabrata.Mycopathologia · 2010Article
- Canadian clinical practice guidelines for invasive candidiasis in adults.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2010Article
- Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location in the United States in 2001 to 2007.Journal of clinical microbiology · 2009Article
- Gain of function mutations in CgPDR1 of Candida glabrata not only mediate antifungal resistance but also enhance virulence.PLoS pathogens · 2009Article
- Trends in species distribution and susceptibility of bloodstream isolates of Candida collected in Monterrey, Mexico, to seven antifungal agents: results of a 3-year (2004 to 2007) surveillance study.Journal of clinical microbiology · 2008Article
- Oral yeast flora and its ITS sequence diversity among a large cohort of medical students in Hainan, China.Mycopathologia · 2007Article
- Epidemiology of invasive candidiasis: a persistent public health problem.Clinical microbiology reviews · 2007Review
- Peptide nucleic acid fluorescence in situ hybridization-based identification of Candida albicans and its impact on mortality and antifungal therapy costs.Journal of clinical microbiology · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We examined the susceptibilities to fluconazole of 559 bloodstream infection isolates of Candida glabrata and grouped the isolates by patient age and geographic location within the United States. Susceptibility of C. glabrata to fluconazole was lowest in the Pacific (44%) and East South Central (47%) regions and was highest in the West South Central region (82%) (regions are as designated by the U.S. Bureau of the Census). Isolates from pediatric patients were virtually all susceptible to fluconazole, whereas the highest frequency of resistance was observed in isolates from patients 16 to 64 years of age.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.